Strong Clinical Validation Biovica's DiviTum TKa assay has demonstrated its effectiveness in early therapy assessment through multiple clinical trials, showcasing its potential to support oncology clinics and pharmaceutical companies seeking reliable monitoring tools.

Expanding Strategic Partnerships Recent collaborations with Yale Cancer Center, Eurobio Scientific, Outcomes4Me, and Palex indicate a growing network in Europe and the US, creating opportunities to introduce and expand sales of the DiviTum TKa test across key markets.

Robust Funding Support With over 13 million USD in total funding and recent financing rounds, Biovica is positioned to scale operations and invest in expanding its sales force to reach more healthcare providers and researchers.

Market Presence and Certification ISO 13485 certification in Europe and CE-labelling for DiviTum TKa enhance credibility and ease market entry in regulated regions, making it easier to engage hospitals, labs, and diagnostic providers.

Leverage US Capabilities Owning a CLIA-certified laboratory in the US allows Biovica to directly offer testing services, providing a unique value proposition to partners interested in expanding their cancer monitoring offerings.